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InfectivitySuper-paramagnetic CD44 MicroBeads (Miltenyi) designed for the isolation of infectious HIV-1 from dilute or
difﬁcult biological samples dramatically enhance the infectivity of bound HIV virions, even if the original viral
suspension is merely incubated with beads. Infection of the CEM T cell line with the NL4-3 virus clone or
primary human CD4 T cells with X4- and R5-tropic clones and a clade C primary virus isolate all showed
accelerated p24 production and larger fractions of infected target cells. Effects could be detected very early;
incubation of virus with the CD44 MicroBeads promoted higher levels of viral integration within the ﬁrst
infection cycle. In summary, CD44 MicroBeads provide the means not only to concentrate dilute viral
samples, but also to directly facilitate within days rather than weeks the in vitro expansion of patient isolates
independent of coreceptor usage and the performance of HIV replication assays that require a large fraction
of infected primary T cells.Published by Elsevier Inc.IntroductionPrimary human CD4 T cells are notoriously inefﬁcient targets for
HIV-1 infection, making in vitro studies of rare or early infection
events difﬁcult to perform even in optimized in vitro culture systems.
In addition, mutant or reporter variants of cloned HIV usually have
reduced infectivity relative to the parental viral strain. Various
strategies have been employed to overcome these difﬁculties such
as pseudotyping virus for more efﬁcient cell entry (Bartz and Vodicka,
1997), concentrating virus by ultracentrifugation, and infection by
“spinoculation” (Forestell et al., 1996). Each of these methods has its
drawbacks. The commonly used envelope protein for pseudotyping,
VSV-G, utilizes acidic endosomal vesicles for virus internalization and
uncoating, which bypasses the normal engagement of CD4 and
coreceptor molecules and any associated signaling events (Aiken,
1997). Viral preparations can be concentrated by high speed
centrifugation at the risk of destabilizing the oligomeric structure of
HIV-1 envelope (Earl et al., 1990), or sedimented onto target cells with
“spinoculation”; however, even infections initiated with very high
multiplicity of infection (MOI) usually infect at best 30–40% of
primary T cells (Bartz and Vodicka, 1997, Noraz et al., 1997). Such high
backgrounds of uninfected cells makes quantitative protein and
molecular assays especially problematic.
A recently released product designed originally for the puriﬁcation
and concentration of infectious HIV-1 from limited amounts of dilute
or difﬁcult clinical specimens may provide a more physiological wayB, Room 324, La Jolla, CA 92093,
.
Inc.to improve infection efﬁciencywithout altering viral genes or proteins.
Based on a superparamagnetic microbead conjugated to an antibody
recognizing CD44, the Miltenyi HIV VitalVirus reagent binds to CD44
molecules that are incorporated into the viral envelope as it buds from
an infected or transfected cell (Tremblay et al., 1998). Although not all
tissues express the CD44H isoform recognized by the CD44 MicroBe-
ads, hematopoetic cell lineages (Dalchau et al., 1980, Flanagan et al.,
1989, Lesley et al., 1993) as well as some cancer cells (Liu and Jiang,
2006) do express high levels of this isoform. CD44 functions as the
hyaluronic acid receptor and has been associated with adhesion
(Shimizu et al., 1989), activation signal transduction (Huet et al., 1989,
Shimizu et al., 1989, Ponta et al., 2003, Hegde et al., 2008), lymphocyte
homing (Berg et al., 1989, de la Hera et al.,1989, Ponta et al., 2003), and
T cell maturation (Marquez et al., 1995, Patel et al., 1995, Ponta et al.,
2003). FollowingMicroBead binding, virions remain attached for up to
several days in culture even after manipulations on magnetic
puriﬁcation columns. Because some preliminary work indicated that
HIV-MicroBead mixtures produced enhanced infection of peripheral
blood mononuclear cells (PBMC) separate from concentration effects
(Miltenyi, personal communication), we decided to investigate this
phenomenon in more detail using primary human CD4 T cells.
Results
Optimization of CD44 MicroBead interaction
To be able to scale up the standard VitalVirus HIV Isolation Kit
protocol (sample size 0.2–1ml) and purify HIV from larger volumes of
culture supernate, we sought initially to optimize reagent conditions
for the ratio of beads to viral preparation volume and mixture
Table 1
Bead ratio, incubation time and virus recovery efﬁciencya.
Code Virus
(ml)
Beads
(ml)
Time
(h)
Volume
reduction
p24 Fold
conc
Protein
recovery
Infectivity
recovery
IU/pg p24
– 0 1.0 1.0 100% 100% 0.36–0.46
U1 2 0.1 1 1.0 1.1 107% 92% 0.31
U2 2 0.3 1 1.0 0.8 82% 94% 0.42
A 2 0.1 1 4.0 1.7–2.5 42–62% 94–165% 0.57–1.30
B 2 0.3 1 4.0 1.7–2.8 43–69% 109–165% 0.58–1.30
C 2 0.1 3 4.0 1.6–2.7 39–68% 112–151% 0.73–1.38
D 15 0.3 1 15.0 4.3–7.7 29–51% 61–121% 0.62–1.51
E 15 0.9 1 15.0 6.9–8.1 46–54% 74–167% 0.55–1.31
F 15 0.3 3 15.0 7.0–8.7 47–58% 58–196% 0.36–1.52
a NL-EGFP virus was prepared as described in Materials and methods. Unconcen-
trated viral supernatants, U1 and U2, were tested once. For all other conditions the
range of values from three experiments are shown. h = hours, conc = concentration,
IU = infectious units.
295V.H. Terry et al. / Virology 388 (2009) 294–304incubation times. Sample volumes of 2 ml and 15 ml were tested at
two bead ratios and incubation times. Controls for the incubation of
virus without further manipulation were included for two bead ratios
(2 ml samples only). Table 1 shows the range of viral infectivity and
p24 protein from three experiments using the NL-EGFP clone, a GFP
reporter variant of the X4 laboratory strain NL4-3, produced in the
CEM T cell line. Unconcentrated samples, U1 and U2, were analyzed
once with the 2 ml sample volume. Treatments of the smaller volume
were the most effective for recovering p24 antigen as measured by
ELISA and infectious units assayed on the reporter HeLa cell line P4R5.
The best viral protein recovery obtained was approximately 60% of theFig. 1. NL-EGFP infection at ﬁxed MOI with concentrated and unconcentrated virus. (A, B) Tw
infectious units (IU, P4R5 cell assay) for 4 h in 1.5 ml total volume. Cells were washed once
primary CD4 cells were infected overnight with MOI=0.05 IU (P4R5) of NL-EGFP, with or wi
GFP expression. (B) Secreted p24, net values. (D) Secreted p24, total values.input; this was most likely due to the presence of non-virion
associated p24 in the original virus preparation. In two of the three
assays, all viral samples incubated with CD44 MicroBeads yielded a
higher infectious titer than could be accounted for by volume
reduction alone during concentration. Such results implied that
virus bound to CD44 MicroBeads had increased infectivity or
accelerated sedimentation onto the adherent reporter cell targets.
To measure the effect of the MicroBeads on T cell infection
independent of virus titer, a ﬁxed number of CEM cells were infected
with 0.05 infectious units (P4R5 cell infectivity assay) of NL-EGFP
virus in a constant ﬁnal culture volume. Fig. 1 depicts a representative
experiment inwhich the fraction of infected cells, as estimated by GFP
expression, increased more rapidly if the virus preparation was
exposed to MicroBeads under any condition including incubation
without subsequent washing or concentration (Fig. 1A). It should be
noted that reporter virus expression of GFP underestimates the actual
number of infected cells when compared to intracellular staining of
p24 expression. All GFP positive cells express high levels of
intracellular p24 (ICp24), but not all p24 positive cells express
detectable GFP (data not shown). Secreted p24 production showed
accelerated kinetics and higher peak levels if virus preparations had
been exposed to MicroBeads, regardless of further puriﬁcation (Fig.
1B). Infection was so efﬁcient in CEM cells with CD44 MicroBead
treatment of virus that almost no viable cells were left to analyze after
7 days of infection. Primary CD4 cell cultures infected with
MicroBead-bound virus also displayed accelerated infection kinetics
by GFP expression and p24 secretion with bead treated virus in three
independent experiments (Figs. 1C and D), although peak GFPo million CEM cells were exposed to NL-EGFP preparations (see Table 1) at MOI=0.05
and cultured for 7 days. Results from one representative experiment. (C, D) Five million
thout 1 h preincubationwith CD44 MicroBeads. Three independent experiments. (A, C)
Fig. 2. CD44 MicroBeads enhance infection by X4 and R5 viruses. Comparison of NL4-3 infections (A, B) of primary CD4 T cells at MOI=0.01 TCID50 with CD44 MicroBead
pretreatment (right panel) and without (left panel). Primary CD4 cells were infected with the R5 clone, JR-CSF (C, E) or clade C, primary X4 isolate 98IN017 (D, F) with an MOI of
0.01 pg p24. Infections were monitored for % infected cells by ICp24 (A, C, D) and soluble p24 (B, E, F). Mean + SEM. n=3, except for A, left panel (n=4) and B, left panel (n=7).
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Fig. 4. CD44 MicroBead treatment increases HIV integration during ﬁrst-cycle infection.
HIV integrants were quantiﬁed after a 6 h infection followed by an 18 h incubation,
with or without TCR/CD28 stimulation. Results from three independent cell donors
(A–C). The detection limit for these assays was 10 copies per PCR. ⁎ Below detection
limit.
297V.H. Terry et al. / Virology 388 (2009) 294–304expression appeared to plateau below 50% in the primary cells. Results
similar to thosewith fresh viral preparations were also obtainedwhen
frozen and thawed viral aliquots were used for infection of CEM and
primary CD4 cells; and the outcomes were not altered whether the
MicroBead incubation occurred before or after the virus preparation
was frozen (data not shown). Based on the results obtained from these
initial experiments, all subsequent CD44 MicroBead interactions were
performed with frozen/thawed virus preparations at the lowest ratio
of 20 μl beads per ml virus, 1 h prior to cell infection.
Infection of primary CD4 cells with X4- and R5-tropic viruses
We next examined the ability of CD44 MicroBeads to enhance in
vitro infections with both X4- and R5-tropic HIV in primary CD4 T
cells. Standard results achieved by infection with the X4 clone, NL4-3,
are shown in Figs. 2A and B. At the peak of infection on day 7 of
culture, approximately 30% of cells expressed ICp24 (Fig. 2A, left) and
106 pg/ml of soluble p24 was produced (Fig. 2B, left). In comparison,
pretreatment of NL4-3 with CD44 MicroBeads increased the fraction
of infected cells to an average of 80%, and did so 3 days sooner (Fig. 2A,
right). The proportion of cells expressing p24 declined thereafter,
probably due to virus induced cytotoxicity. The kinetics of soluble p24
productionwas accelerated as well, reaching amaximal level by Day 4,
equal to that of untreated virus infection at Day 7 (Fig. 2B, right). To
conﬁrm that the enhancement effect of CD44 MicroBead treatmentFig. 3. Enhanced infection results in higher levels of HIV integrants and replication
competent infected cell units. Primary CD4 cells were infected with the R5 clone, JR-CSF
(left panels) or clade C, X4 isolate 98IN017 (right panels) with or without pretreatment
with CD44 MicroBeads. At the end of 2 weeks of culture, genomic DNA was isolated for
qPCR quantiﬁcation of HIV integrants per 200 ng input DNA (A) and harvested cells
were reactivated with αCD3/αCD28 to determine replication competent infectious
units per million (IUPM) by limiting dilution assay (B). Results from three independent
cell donors shown (x axis: A–C). nd=not done.was independent of coreceptor tropism, preparations of the R5 HIV
clone JR-CSF were used to infect primary CD4 cells. Without
MicroBead treatment, JR-CSF infected up to 5.5% of cells (Fig. 2C);
however, 10 to 30% of cells showed ICp24 expression following
infection with the MicroBead treated virus preparation. Levels of
secreted p24 antigen increased earlier and reached a higher plateau
following infection with treated virus (Fig. 2E), similar to results seen
with X4 NL-EGFP infection. As reported by other investigators (Blanco
et al., 2001, Grivel et al., 2000, Lawson et al., 2004), infection with the
R5-tropic clone of JR-CSF resulted in less cell death than infectionwith
the X4-tropic clone of NL4-3. The JR-CSF infected cell cultures were
maintained for 14 days, at which point cells with integrated HIV DNA
and replication competent virus (infectious units per million cells,
IUPM) were assayed. MicroBead treatment increased the number of
integrated HIV-1 DNA copies from 5 to 35 fold (Fig. 3A), reaching up to
a million copies/200 ng total DNA (30,000 cell equivalents) in some
cases, and increased IUPM from 3 to 105 fold (Fig. 3B).
To test the general utility of the MicroBead reagent for expanding
clinical virus isolates, infections were performed using a clade C, X4
primary isolate, 98IN017. An original aliquot of virus from the NIH
AIDS Research and Reference Reagent Program had been expanded in
PBMC culture and stored frozen at a relatively low titer of
approximately 100,000 pg p24/ml. Infections with virus alone yielded
variable results in cells from 3 different donors, with maximum
infected cell fractions reaching less than 2% (Fig. 2D) and soluble p24
production levels of 2200 to 8400 pg/ml after 14 days of culture
(Fig. 2F). Virus aliquots pretreated with MicroBeads exhibited
improved infection capacity reaching maximal target cell infection
rates of 3 to 13.5% (Fig. 2D) and soluble p24 production of 25,000 to
56,000 pg/ml (Fig. 2F) at Day 10. Consistent with the higher viral
protein production, the number of integrated HIV copies and IUPM
assayed at Day 14 also increased with virus incubation with MicroBe-
ads. Untreated viral infections produced 4400 to 50,200 integrants per
200 ng input DNA, while infections with CD44 MicroBead preincu-
bated virus yielded 28,500 to 96,800 copies (Fig. 3A). The frequencies
of replication competent infected cells were more modest, increasing
2.5 or 5 fold with bead treatment (Fig. 3B).
Enhancement of the ﬁrst infection cycle
In addition to improvements in infection, we observed that resting
primary CD4 cells exposed to CD44 MicroBead treated virus tended to
form microscopically visible clusters that remained up to a week in
culture. Infected cells that were stimulated with αCD3 and αCD28,
however, formed blasts and did not maintain as much cell-to-cell
298 V.H. Terry et al. / Virology 388 (2009) 294–304contact. To ascertain whether the faster infection kinetics observed
were due to a more efﬁcient initial infection or more efﬁcient viral
spread through enhanced cell-to-cell contact (Dimitrov et al., 1993),
we performed quantitative HIV integrant analysis 24 h after exposing
cells to virus. MicroBead treatment of virus increased the amount of
detectable HIV integration (copies per 200 ng genomic DNA) from 1.5
fold to as much as 90 fold (Fig. 4). In some cases, even cells that had
not been stimulated with αCD3 and αCD28 antibodies showed more
HIV integration, if the virus preparation had been incubated with
MicroBeads prior to infection. This suggested that MicroBeads bound
to virions could affect early infection events, either through direct
interaction with the CD44 molecules on cellular membranes or more
rapid sedimentation onto the targeted T cells.
To address whether centrifugation steps during post infection cell
washes were creating a “spinoculation” effect, CEM cell aliquots were
exposed to NL-EGFP for 4 h in a standard limited volume, and then
diluted with excess medium. Subsequent supernatant sampling for
p24 production was performed in a manner that did not subject the
continuing culture to centrifugal forces. The fraction of cells exhibiting
productive infection by GFP expression and the levels of p24 secretion
were at least as high as those seen in earlier experiments with
MicroBead treated virus (data not shown). Thus, while virion–
MicroBead complexes may settle more quickly onto cells than virus
alone, the added g forces from centrifugation during cell washes did
not appear to contribute to enhanced infection.Fig. 5. CD44 MicroBead treatment of virus produced from CD44H(−) and (+) cells. Primary
HeLa P4R5 (CD44H+), and CEM (CD44H+) cells, with or without prior incubation with CD
secreted p24, assayed by ELISA (B). n=3 except at one time point, as noted. Mean+SEM. Fol
produced by various cell lines (x axis), assessed one day after infection in unstimulated celSeparation of MicroBead effects on virus versus cells
The cell clustering seen in both uninfected and infected cultures
exposed toMicroBeads and the increased amounts of virus integration
found in unstimulated cells exposed to MicroBead treated virus
suggested a direct interaction between target CD4 T cells and CD44
MicroBeads. To separate any cell signaling events induced by viral
proteins from potential MicroBead induced effects, NL4-3 prepara-
tions were generated to preclude virion binding to the MicroBeads.
Virus was produced by plasmid transfections into either HeLa P4R5
cells expressing CD44H (hematopoietic isoform) or 293T cells, which
do not bear CD44H and cannot bind the speciﬁc αCD44 antibody
conjugated to the MicroBead reagent (clone DB105-2G12.1; data not
shown). Because the infectious titer of HIV (IU/pg p24) produced in
293T cells is about 6 fold lower than that of virus produced in CEM or
P4R5 cells (data not shown), we attempted to compensate for this
factor in our experimental design. Therefore, the primary CD4 cell
infections were performed using a relatively large ﬁnal volume for
each of the virus stocks, resulting in much lower cell and virus
concentrations than our standard infection procedure with CEM or
primary lymphocytes. As expected, virus produced from CD44H
expressing cells and treated with the MicroBead reagent generated
infections with markedly accelerated intracellular and secreted p24
production relative to parallel infections with untreated virus or
MicroBead treated virus produced in 293T cells lacking CD44H (Figs.CD4 T cells were infected with NL4-3 produced from transfection in: 293T (CD44H−),
44 MicroBeads. The fraction of infected cells was measured by ICp24 with FACS (A) and
d change in CD25 (C) and CD69 (D) expressionwith CD44 MicroBead treatment of virus
ls. Mean and range of three experiments.
Table 2
Single-cycle infection, integrant assay with CD44 and CD45 reagentsa.
Reagent Integrants (copies/200 ng DNA)
A B C
– 6 NDb NDb
CD44 MB 265 113 136
Bio-SA αCD44 49 23 43
Free αCD44 11 NDb NDb
CD45 MB 149 101 44
299V.H. Terry et al. / Virology 388 (2009) 294–3045A and B). MicroBead pretreatment of virus produced in CEM T cells
resulted in infections with approximately 20 fold more infected cells
(22 to 48% ICp24 positive) and secreted p24 (280,000 to 780,000 pg/
ml). Infections with virus produced in P4R5 cells were less robust in
general: however, CD44MicroBead treatment caused an unexpectedly
large magnitude of enhancement, with over 100 fold increase in
infected cells (31 to 84% ICp24 positive) three days earlier (Day 4)
than peak infection with untreated virus. In contrast, virus produced
in 293T cells showed only a 2 fold change in infection efﬁciency withFig. 6. Virus treatmentwith otherαCD44 reagents andCD45MicroBeads. Treatmentswith
CD44 MicroBeads, streptavidin-complexed biotinylated αCD44, free αCD44 and CD45
MicroBeadswere compared in spreading CEM infectionswith NL-EGFP (A, B). The fraction
of CEMcells expressingGFPwasanalyzedby FACS(A)and soluble secretedp24wasassayed
by ELISA (B). Mean+SEM of three experiments. (C) CD69 expression in unstimulated
primary CD4 cells, measured one day after exposure toαCD44 orαCD45 reagents alone, or
in conjunction with NL4-3 infection. Mean and range of three experiments.
a NL4-3 virus was treated with CD44 or CD45 reagents for 1 h before infection and
stimulation of primary CD4 cells from three independent donors, as described in
Materials and methods. bio-SA = complexed with biotin–streptavidin.
b ND, Not detected; Below 5 copy detection limit.CD44 MicroBead pretreatment. Such results indicate that physical
complexing of CD44 MicroBeads with virus is required for the
observed enhancement of HIV infection. Despite the lower infectivity
of 293T generated virus (as determined in a P4R5 cell assay), the
untreated 293T virus preparations induced better infection (4 to 10%
ICp24 positive cells and 71,000 to 166,000 pg/ml secreted p24) than
did either the untreated P4R5 or CEM generated virus preparations
under these diluted inoculum conditions.
To determine whether contact between CD44 MicroBeads alone
and target T cells can induce cellular changes, ﬂow cytometric
phenotype analysis was performed on Days 1, 4, and 7 following
infection to measure expression of surface activation markers, CD25
(IL2 receptor α chain) and CD69, a very early marker of T cell receptor
induced activation (Testi et al., 1989). Despite high levels of CD44 on
the surface of T cells, modulation of cell membrane activation markers
after exposure to CD44 MicroBeads was detected in only a minor
subpopulation of the resting CD4 target cells. The largest alteration of
CD25 and CD69 expression was seen on Day 1 after MicroBead
treatment (Figs. 5C and D). CD25 expression in cell controls without
bead treatment ranged from 0.6% to approximately 6% on Day 1;
exposure to MicroBeads resulted in slight increases of 1.3 to 2.5 fold,
the magnitude of which varied between cell donors, but not with the
presence of virus (Fig. 5C). CD69 expression was detected on a
maximum of 3% of unstimulated CD4 T cells, one day following
exposure to virus mixed with MicroBeads (Fig. 5D). CD69 expression
increased 3 to 13 fold after 1 day of culture from 0.1 to 0.8% in
untreated cells and 1.0 to 2.6% in cells exposed to beads alone or in
combination with virus. If data from both the uninfected and infected
cell samples were pooled, bead treatment induced signiﬁcant changes
in both CD25 and CD69 expression at this early time point
(p=0.0005, Wilcoxon Matched Pairs Signed Rank Test). In contrast,
stimulation with combined TCR/CD28 cross-linking caused virtually
all cells to express CD69 after one day, and CD25 by Day 4. No
additional effects of MicroBead treatment could be detected in this
setting (data not shown).
Enhancement of infection requires multimeric antibody reagents
To further investigate the mechanism(s) of enhanced infection by
CD44 MicroBeads, we compared infections achieved in CEM cells by
NL-EGFP virus preparations that were pretreated with one of the
following: CD44 MicroBeads, free αCD44 antibody, biotinylated
αCD44 antibody complexed with recombinant streptavidin, and
CD45 MicroBeads. Only the multivalent reagents (biotinylated
αCD44+streptavidin and CD45 MicroBeads) enhanced infection
relative to the positive control of CD44MicroBead treatment, although
with 1–2 day delayed kinetics (Figs. 6A and B). When tested in the
single-cycle viral integrant assay, virus treated with CD44 MicroBeads
yielded the greatest number of integrants followed by CD45 MicroBe-
ads and biotinylated-streptavidin complexed αCD44 (Table 2). Use of
free αCD44 treatment produced similar levels of integrants as virus
alone (bthe 5 copy detection limit). FACS analysis of CD25 expression
Fig. 7.Model of CD44MicroBead interactions with HIV and target cells. Binding of CD44
MicroBeads to virus particles may accelerate sedimentation onto target cells (1).
Simultaneous binding of MicroBeads to virions and cell membrane CD44 may stabilize
virion–CD4 interactions and promote coreceptor binding. CD44 MicroBead attachment
to cellular CD44 may initiate intracellular signaling that promotes infection (2). Also,
virus may spread more efﬁciently due to cell clustering induced by activated adhesion
molecules or by cross-linking of cells directly through MicroBead binding (3).
Illustration not to scale.
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reagents alone, virus alone, or virus preincubated with αCD44 or
αCD45, revealed little difference from uninfected, untreated cells.
However, incubation with CD45 MicroBeads resulted in a mild
increase in CD69 expression, from less than 1% in untreated cells to
about 5% following CD45 bead exposure in both uninfected and
infected cells (Fig. 6C). None of these observed changes in CD25 or
CD69 expression were signiﬁcant (p=0.1 by Wilcoxon Matched Pair
Ranked Sign Test).
Discussion
Using a T cell line and primary CD4 lymphocytes, this study
conﬁrms and expands upon a prior anecdotal observation of increased
HIV infectivity with virus preparations treated by the Miltenyi
VitalVirus HIV Isolation Kit. Speciﬁcally, we demonstrate accelerated
infection kinetics, increased peak levels of infected cells and virus
production, independence of virus clade and coreceptor tropism, and
the requirement for CD44H antigen inclusion in the viral envelope.
We have endeavored to understand how CD44 MicroBead treat-
ment improves HIV-1 infection of T cells by using comparisons with
non-bead associated αCD44 antibody reagents and MicroBeads
conjugated to αCD45 antibody (CD45 MicroBeads). Our results
demonstrate that maximal enhancement of infection occurs when
MicroBeads are conjugated to the αCD44H monoclonal antibody.
Surprisingly, CD45 MicroBeads appeared just as effective in accelerat-
ing HIV infection as multivalent αCD44 streptavidin complexes and
almost as effective as CD44 MicroBeads, even though it is known that
CD45 molecules are excluded from budding virions (Tremblay et al.,
1998, Nguyen et al., 2003, Chertova et al., 2006). The signiﬁcance of
these ﬁndings is difﬁcult to assess, however, given the 5 fold range of
antibody concentrations among the CD44 reagents tested, and the 10
to 50 fold higher antibody concentration of the CD45 MicroBead
reagent. The increased multivalency of αCD44 antibody, present on
the surface of MicroBeads and in the streptavidin-αCD44-biotin, is
correlated with the effectiveness of HIV infection enhancement. Thus,
for reagents containing αCD44, it is possible to envision that
complexing of αCD44 with HIV, as well as delivery of virions to target
T cells, is more efﬁcient when virus particles are associated with more
αCD44 antibody, but not necessarily with a paramagnetic particle. In
the case CD45 MicroBead effects, it is well known that primary T
lymphocytes express high levels of membrane CD45 (Schwinzer,1989,
Thomas, 1989), and modulation of CD45 protein tyrosine phosphatase
activity (Clark and Ledbetter, 1989) can negatively or positively affect
signaling pathways dependant on the receptor or endpoint assayed
(Thomas, 1995). Elucidation of the mechanism(s) involved in CD45
MicroBead interaction with T cells will require additional work that is
outside the scope of our current research.
Another experimental ﬁnding, which begs further explanation, is
the increased expression of cell surface activation molecules seen in a
small fraction of unstimulated cells following exposure to complexed
αCD44 antibody, CD44 MicroBeads or CD45 MicroBeads. Because
CD44 and CD45 are both highly expressed on primary T cells, it is
possible that exposure to these reagents induces receptor cross-
linking and initiates a minimal cell activation event. It is important to
note that any changes in functional status of cells following interaction
with these MicroBead reagents are dependent primarily on cell
surface expression of antigen and the degree of cross-linking induced
by the cognate monoclonal antibody complexed to the MicroBeads,
and not to factors inherent to the MicroBeads themselves (Grützkau
and Radbruch, 2008; Schmitz, 2008). In addition, the interaction of
multivalent antibodies with cell surface antigens during prolonged
periods at 37 °C (as performed here) is likely to cause aggregation and
internalization of membrane receptors, resulting in modulation of
some gene expression. Never the less, none of the complexed αCD44
or αCD45 reagents induced changes in CD25 or CD69 expression thatwere signiﬁcantly greater than those observed in untreated cell
cultures or during infections with virus preparations unable to
complex with CD44 MicroBeads (non-CD44H bearing virions). There-
fore, any contribution of CD44 MicroBeads to enhancement of viral
infection through direct effects on cellular CD44 function would
appear to be minor.
A more likely scenario to explain the effect of MicroBeads on HIV
infection is a model inwhich CD44MicroBead binding simultaneously
to both virions and target cells contributes to the increase in apparent
viral infectivity (Fig. 7). Incubation of CD44 MicroBeads with virions
that contain cellular CD44H in their envelope allows direct virus
binding to beads. Although MicroBeads are 50 nm in diameter and do
not sediment in aqueous solution, CD44 MicroBeads attached to HIV
in multimeric complexes may display very different characteristics.
The added mass of the MicroBead along with the highly multivalent
character of CD44 MicroBead–virion interaction may help sediment
virus onto target cells so effectively over the incubation period that
subsequent centrifugations to remove unbound virus do not create
any additional spinoculation effect. As a second contributing factor,
αCD44 antibodies conjugated to the MicroBeads could physically
bridge virus to target cells through engagement of unoccupied
antibody binding sites with CD44H antigen expressed on the cell
membrane. Given the high afﬁnity of gp120 binding to the CD4
receptor (4–8 nM for HXB2 and YU2 gp120; Stricher et al., 2008), and
the CCR5 coreceptor for R5 virus (JR-FL; Doranz et al., 1999), the
∼1 nM afﬁnity of typical antibody-antigen interactions (O'Shannessy
et al., 1994, Katsamba et al., 2006) is not likely to provide any
enhancement of initial contact between virions and cell surface
molecules. However, due to the large number of antibody molecules
conjugated to CD44MicroBeads, interactionwith the highly expressed
CD44 molecule on target cells could be expected to generate high
avidity binding and stabilize virus–cell contact. αCD44 mediated
tethering may prolong CD4-gp120 engagement, allow coreceptor
reorganization and binding, and facilitate the coupling of other
301V.H. Terry et al. / Virology 388 (2009) 294–304envelope embedded cellular proteins with their CD4 cell counterparts,
some of which are known to increase virus infectivity (Arthur et al.,
1992, Arthur et al., 1995, Chan et al., 1995, Cantin et al., 2005). While
virus associated ICAM-1 binding to cellular LFA-1 is an example of a
high afﬁnity interaction enhancing infectivity 10 fold (Fortin et al.,
1997, Rizzuto and Sodroski, 1997) or even 100 fold (Fortin et al., 1998),
the relatively weak interaction between HLA-DR in virion envelope
and cellular CD4 can also promote virus entry, resulting in two-fold
faster infection kinetics (Cantin et al., 1997). CD44 MicroBead
interactions with HIV may create similar types of phenomena.
In addition, CD44 engagement by certain antibodies is known to
induce adhesion and activation signal transduction (Huet et al., 1989,
Shimizu et al., 1989, Ponta et al., 2003). In the work reported here, we
observed that cells exposed to CD44 MicroBeads (or multimeric
αCD44) formed small clusters independent of the presence of virus in
the complex. Such clustering would be expected to facilitate far more
efﬁcient viral transmission through direct cell-to-cell contact, in
contrast to infection achieved with soluble virus (Dimitrov et al.,
1993). The clustering effect induced by MicroBeads may be the direct
result of CD44′s adhesion function, or an indirect effect of signal
transduction by CD44 activation of other adhesion molecules, such as
LFA-1. It has been reported that binding of RANTES to CD44 can lead to
p44/p42MAPK signaling and improved HIV infection (Roscic-Mrkic et
al., 2003), and a similar mechanism may play a role in our
observations. While not statistically signiﬁcant, the increase in both
viral integration and CD69 expression following cell exposure to viral
preparations with CD44 or CD45 MicroBeads suggests that engage-
ment of CD44 and CD45 on cell membranes may cause an effect that
could, at least partially, explain observed increases in viral infectivity.
The ability to accelerate infection of CD4 T cells has practical utility
for both the production of virus stocks and the improvement of viral
assay systems. Shortening the culture time necessary to reach high
viral titers decreases the consumption of tissue culture reagents
during virus expansion. Production of high titer virus preparations can
facilitate infection of a larger proportion of primary cell targets and
enable individual cell analysis, as has already been reported for
infection with HIV-1 concentrated by CD44 MicroBeads (Mitchell et
al., 2008). Most importantly, application of CD44 MicroBeads to the in
vitro expansion of primary clinical virus isolates may allow for
genomic and phenotypic characterizations that would otherwise not
be possible. Additionally, tissue culture based assays that measure
viral products may be enhanced by the inclusion of CD44 MicroBeads,
which can shorten the time necessary to cross a detection threshold,
or potentially increase the sensitivity of an assay by acting as a
biological signal ampliﬁer.
We have demonstrated improved HIV infection of primary CD4 T
cells with the use of CD44 MicroBeads. How well these MicroBead
reagents canperform to enhance infection ofmacrophage ormicroglial
cells remains to be determined. The amount of CD44 expressed on
macrophages could be as high as that on circulating lymphocytes
(Haynes et al.,1989, Koller et al.,1996, Lee et al., 2001), but the adherent
growth properties of macrophages would preclude MicroBead forma-
tion of cell clusters for increased cell-to-cell transmission. Still, the
ability of virion-bound MicroBeads to settle onto cells more rapidly
and interact with cell membrane CD44 molecules may provide a
noticeable improvement to current infection methods. In conclusion,
CD44 MicroBeads provide a practical means to enhance HIV infection
simply by binding to CD44H-containing virions, in addition to their
ability to purify and concentrate infectious virus from solution.
Materials and methods
Cell lines and media
293T cells (DuBridge et al., 1987) were a kind gift from Dr.
Nathaniel Landau and maintained in Eagle's MEM with 2× vitaminsand nonessential amino acids (Quality Biologicals, Gaithersburg, MD)
supplemented with 2 mM glutamine (Invitrogen, Carlsbad, CA) and
10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento,
CA). P4R5 MAGI cells were obtained from the NIH AIDS Research and
Reference Reagent Program (Germantown,MD); they areHeLa P4 cells
stably transduced to express human CD4 and CCR5, and with β-
galactosidase under transcriptional control of theHIV-1 LTR (Charneau
et al., 1994). They were maintained in Dulbecco's MEM supplemented
with 2 mM glutamine, and 100 U/ml penicillin/100 μg/ml strepto-
mycin (Invitrogen, Carlsbad, CA), and 10% FBS (Gemini Bio-Products,
West Sacramento, CA) (D10) with 1 μg/ml puromycin (Calbiochem,
Gibbstown, NJ). CEM cells (American Type Culture Collection,
Manassas, VA) were cultured in RPMI 1640 (Invitrogen, Carlsbad,
CA) with 10% FBS from Cambrex (Walkersville, MD) (R10).
Reagents and antibodies
RosetteSep Human CD4+ T Cell Enrichment Kit was purchased
from StemCell Technologies (Vancouver, BC, Canada). Prescreened,
pooled human AB serum for primary CD4 T cell culture was purchased
from Omega Scientiﬁc (Tarzana, CA). Dulbecco's Phosphate Buffered
Saline without calcium or magnesium (PBS) was from Mediatech
(Herndon, VA). Formaldehyde for ﬂow cytometry samples was
purchased as a 10% solution from Polysciences of Warrington, PA.
Potassium ferricyanide was from Mallinkrodt Baker (Phillipsburg, NJ)
and 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal) was
acquired from Apex Bioresearch Products (San Diego, CA). Recombi-
nant human IL-2 (Lahm and Stein, 1985) (rIL-2) was obtained from
the NIH AIDS Research and Reference Reagent Program. Recombinant
human IL-15 (rIL-15) and human interferon β1a (IFNβ) were
purchased from R & D Systems (Minneapolis, MN). HIV VitalVirus
kits containing CD44 MicroBeads, buffers and magnetic columns,
biotinylated αCD44 complexed with streptavidin, free αCD44, and
CD45 MicroBeads were generous gifts from Miltenyi Biotec, Bergisch
Gladbach, Germany. FuGene6 lipid mediated transfection reagent was
from Roche Applied Science (Indianapolis, IN). Sigma Chemical
Company (St. Louis, MO) was the source for Histopaque-1077 and
all other chemicals.
Goat anti-mouse IgG+M (H+L) was from Kirkegaard and Perry
Laboratories (Gaithersburg, MD). Anti-CD3, αCD28, APC-αCD25, and
APC-Cy7-αCD69 were purchased from BD Biosciences (San Jose, CA).
PE-αHIV-1 p24/gag clone KC-57 was obtained from Beckman Coulter
(Carlsbad, CA).
Negative selection of primary human CD4 T cells
Blood from healthy donors was collected by venipuncture into
polypropylene syringes containing sodium heparin according to
institutional review board approved protocols. Buffy coats were
incubated with 1/10 volume of RosetteSep CD4 T cell enrichment
cocktail at room temperature for 20min, dilutedwith onevolumeof PBS
containing 2% human AB serum (2% HAB/PBS), then CD4 T cells were
separated from the remainder of PBMC and red cell rosettes by density
gradient centrifugation. CD4 cells werewashed twicewith 2%HAB/PBS
and resuspended in RPMI 1640 medium supplemented with 2 mM
glutamine,100 U/ml penicillin/100 μg/ml streptomycin, and 5% human
AB serum (R5HAB). Cells were infected overnight, or held overnight in
R5HAB growth medium prior to a 6 h infection the following day.
Viruses
X4 viruses NL4-3 and NL-EGFP (a kind gift from Dr. Naoki
Yamamoto, Tokyo Medical and Dental University), were grown from
starter viral stocks in CEM cells for 13 to 17 days. At harvest, cells and
large debris were removed by centrifugation and viral aliquots were
stored at−80 °C. Alternatively, plasmids pNL4-3 (Adachi et al., 1986),
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were transfected into 293T cells with FuGene6, according to the
manufacturer's protocol. Cell-free supernatants were harvested two
days later. X4 tropic viruses were expanded in CEM cells while PHA-
stimulated healthy control PBMCwere infected to grow JR-CSF R5 viral
stocks. The clade C X4 primary patient isolate 98IN017 (NIH AIDS
Research and Reference Reagent Program) was cultured initially in
PHA activated healthy control PBMC then expanded with hetero-
logous healthy control CD4 T cells. For comparison of CD44H-lacking
and -containing virus preparations, P4R5 cells were transfected in
parallel with 293T cells and supernatants ﬁltered through a 0.45 μm
pore before storage at −80 °C. For all cultures, secreted p24 was
measured by ELISA (Alliance HIV-1 p24 kit, Perkin Elmer, Waltham,
MA) according to manufacturer's instructions. Infectious virus titer
was measured by limiting dilution in CEM cells and TCID50 calculated
by the Reed–Muench Accumulative Method (Reed andMuench,1938)
or by the P4R5 MAGI LTR β-galactosidase, blue cell reporter cell assay
for infectious units (Day et al., 2006).
Infections
CD44 MicroBead pretreatment involved combining fresh or
thawed virus preparations with CD44 MicroBeads at speciﬁed ratios
and times at 4 °C with gentle rotation or rocking. Treated virus was
then either added directly to cells or loaded onto Miltenyi magnetic
columns and allowed to enter columns by gravity ﬂow. Bound virus
was washed and eluted according to manufacturer's instructions into
0.5 or 1 ml R10 medium to achieve desired sample volume reduction.
Aliquots were stored at−80 °C; p24 and infectious titer were assayed
by ELISA or dilution onto P4R5 cells, respectively.
CEM infectionswere performed by resuspension of pelleted cells in
a small ﬁxed volume of virus solution in R10 medium. GFP expression
levels of the NL-EGFP reporter virus were monitored by FACS analysis;
secreted p24 was assayed in culture supernatant by ELISA.
Primary CD4 T cells were incubated with viral preparations either
overnight or for 6 h in the single infection cycle assay, then washed 4
times with 2% HAB/PBS before resuspension in R5HAB growth
medium. Where noted, mock infections were performed with CD44
MicroBeads which had been incubated for 1 h at 4 °C in growth
medium alone, then added to cells for 6 h . Unstimulated cells were
kept in 14 ml polypropylene round bottom tubes in R5HAB medium.
Stimulated cells were cultured in microplates with ﬂat-bottom wells
coated withαCD3 andαCD28 followed by the addition of cytokines as
described previously (Spina et al., 1997, Spina et al., 2000). Cell and
supernatant aliquots were removed for FACS analysis and p24 ELISA at
speciﬁed days or upon addition of fresh medium. Integrated HIV DNA
analysis and IUPM titer were performed on Day 14, where noted.
Infections with free or biotin–streptavidin complexed αCD44
(same clone as in MicroBead reagent) or CD45 MicroBead virus
treatment were performed as described above. Mock infections were
also performed with αCD44 or αCD45 reagents alone. Final
concentrations of CD44 or CD45 antibody were 0.2, 0.8, 1 and 10 μg/
ml for CD44 MicroBeads, biotin–streptavidin complexed αCD44, free
αCD44 and CD45 MicroBeads, respectively.
Flow cytometry analysis
Aliquots of 5×105 cells were taken from culture, washed with PBS
and surface markers were stained with APC-Cy7 labeled (3 μl) or APC
labeled (5 μl) antibodies in 200 μl of PBS containing 2% FBS and 0.1%
sodium azide (FACS Staining Buffer) for 30 min at 4 °C protected from
light. Cells were washed twice with 1 ml FACS Staining Buffer and
ﬁxed with 0.5% formaldehyde in PBS. GFP quantiﬁcation was
performed on washed cells, which were immediately ﬁxed. Intracel-
lular p24 analysis was performed by a modiﬁcation of the method of
Bartz and Vodicka (1997). Brieﬂy, cells were treated at 4 °C with BDCytoFix/CytoPerm for 20 min, washed twice with BD Perm Wash
solution, then stained with 50 μl of 1/100 dilution of PE conjugated
αp24 for 30 min at 4 °C. Cells were washed and resuspended in 0.5%
formaldehyde in PBS. Multiparamter data were acquired on a BD
FACSCanto and analyzed with FACSDiva software (BD Biosciences).
Single-cycle infection, viral integrant assay
Isolated primary CD4 cells were held overnight in medium,
infected for 6 h, washed, and stimulated overnight. Cells were
harvested for FACS analysis of surface activation markers CD25 and
CD69 and genomic DNA prepared with the Qiagen Blood and Cell
Culture DNA Mini kit according to kit instructions (Qiagen, Valencia,
CA). This kit isolates 20–150 kb DNA fragments, obviating the need to
remove partially reverse transcribed or unintegrated circular viral
cDNA prior to integrant analysis. DNA was quantiﬁed by UV spectro-
photometry at 260 nm with correction for absorbance at 320 nm. Up
to 200 ng of infected cell genomic DNAwere assayed by TaqMan real-
time PCR for HIV-1 NL4-3 gag with the following primers (Integrated
DNA Technologies, Coralville, IA): forward 5′ – AAAAGAGACCATC-
AATGAGGAAGC – 3′, reverse 5′ – TGGTGCAATAGGCCCTGC – 3′, probe
5′ - 6-FAM- CAGAATGGGATAGATTGCATCCAGTGCA -BHQ-1 - 3′. For
quantiﬁcation of clade C X4 isolate 98IN017 and R5 clone JR-CSF
integrants, pol primer sequences (Rousseau et al., 2004) forward
pol-15 5′ – TACAGTGCAGGGGAAAGAATA – 3′, reverse pol-4
5′ – CTGCCCCTTCACCTTTCC – 3′, and probe Polp 1 5′ - 6-FAM-
TTTCGGGTTTATTACAGGGACAGCAG-BHQ-1 - 3′ were used instead.
Duplicate 25 μl PCR reactions containing TaqMan Universal Mastermix
(Applied Biosystems, Inc., Foster City, IA), 900 nM each forward and
reverse primer, and 200 nMprobewere incubated at 50 °C×2min and
95 °C×10 min, followed by 45 cycles of 95 °C×15 s and 60 °C×1 min
on an ABI Prism 7700 Sequence Detector (Applied Biosystems, Inc.).
Sequence Detector software was used to calculate Ct values, and copy
number standard curves were derived from dilutions of NcoI
linearized pNL4-3 plasmid in 200 ng uninfected CD4 T cell genomic
DNA. The detection limit for each assay was deﬁned as the lowest
amount of standard that could be ampliﬁed in both reactions with Ct
values distinct from the next highest concentration.
Infectious units per million cells (IUPM) assay
Replication competent infectious titer was measured with a
modiﬁcation of the AIDS Clinical Trials Group Lab Manual HIV
Quantitative PBMC culture protocol revised version 2.0 May 2004
(Lathey et al., 1994) based on maximum likelihood estimation of
infectious unit concentration (Myers et al., 1994). Day 14 infected cells
were washed twice with 2% HAB/PBS, counted, and plated in
duplicate wells of 96-well plates coated with αCD3 and αCD28
antibodies. A total of 105 cells were plated neat and at ﬁve serial 1:5
dilutions with autologous uninfected Day 14 cells in a ﬁnal volume of
200 μl per well. The dilution series was also plated in uncoated wells
(unstimulated) to control for carry over of free virions. After 7 days,
conditioned medium was taken and assayed for soluble p24 with the
Perkin Elmer Alliance HIV-1 p24 ELISA kit. Positive wells were deﬁned
as having at least 50 pg/ml p24 above input. Outcomes were
compared to a table of maximum likelihood estimates and goodness
of ﬁt P values received from Don Brambilla of New England Research
Institutes, Inc. Results were normalized to infectious units per million
and valid assays had P values greater than 0.2.
Statistical analyses
Prism version 4 (GraphPad Software, Inc., San Diego, CA) was used
for statistical analysis. Wilcoxon Two Sample Test was used to
determine effect of virus on FACS expression data before pooling
CD44 positive and negative viruses or all samples for CD44 MicroBead
303V.H. Terry et al. / Virology 388 (2009) 294–304effect on cells. FACS and HIV integrant data were tested by Wilcoxon
Matched Pairs Signed Rank test for signiﬁcance at pb0.05 of bead or
reagent treatment.
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